欧洲杯竞猜

      Home
      Who We Are
      What We Do
      Corporate Responsibility
      News
      Careers
      Investors
      Patients and HCPS
      Contact us
      Careers | Investors | Patients and HCPS | Contact us
      Global
      中文站
      Careers Investors Patients and HCPS Contact us
      Home / Company News / Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
      Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
      Date:2021-10-14

      Beijing, China/Bridgewater, New Jersey U.S., October 14th, 2021Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic. The two studies were conducted separately in subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567).


      The primary purpose of these 26-week studies was to assess the equivalence in treatment-induced (TI) immunogenicity between GL-GLA and the reference biologic using pre-specified similarity margins. The secondary objectives were to assess the equivalence in efficacy and evaluate safety. Both studies concluded there was equivalent TI immunogenicity. Efficacy estimates between groups were within pre-specified similarity margins and concluded to be equivalent. Safety endpoints were comparable between GL-GLA and the reference biologic.


      About Gan & Lee

      Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin), mixed protamine zinc lispro injection (25R) (Prandilin25), aspart 30 injection (Rapilin30), and one human insulin injection approved in China – mixed protamine human insulin injection (30R) (Similin30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine).


      In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and working on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 

       


      Copyright 2021 Gan & Lee Pharmaceuticals Co Ltd . All Rights Reserved.
      Our websites

      Subscribe

      I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.

            欧洲杯竞猜